FDA Approves Trial To Treat Opioid Addiction With CBD

Nantheia ATL5 is an oral product with 100mg of CBD per soft gel capsule

The U.S. Food and Drug Administration (FDA) has approved an investigational new drug (IND) application for a clinical trial to evaluate CBD as an adjunctive method to treat opioid use disorder.

Biotech pharma company Ananda Scientific Inc. announced in January 2022 the FDA’s approval for the clinical trial evaluating Nantheia ATL5, an investigational drug using CBD as an adjunctive treatment for opioid use disorder. The study will be conducted at the University of California, Los Angeles (UCLA).

Nantheia ATL5 is an oral product with 100mg of CBD per soft gel capsule utilizing Liquid Structure technology, licensed from the Israeli pharmaceutical company Lyotropic Delivery Systems, which enhances the effectiveness and stability of CBD.

Pre-clinical and initial clinical studies show that ANANDA’s Liquid Structure technology would enhance the effectiveness and stability of CBD. 

To Read The Rest Of This Article On Forbes, Click Here

Click to comment

Leave a Reply

Your email address will not be published.

CHAMPS Smoke Shop Report, or ‘CSS’, online source for the updates and innovations on the smoke shop scene. News and information are geared strictly to accessories retail channels, with distribution limited to retailers that Smoke Shop products and wholesalers.


Stay informed with the most up-to-date industry news to help you grow your business: subscribe to our newsletter below!

To Top